胸腺五肽对接受单纯放疗或联合放、化疗鼻咽癌患者的远期疗效  

THEEFFECT OF THYMOPENTIN ON LONG-TERM OUTCOMES OF PATIENTS WITH NASOPHARYNGEAL CANCER

作　　者：谢国丰[1] 贾保昌[1] 田允鸿[1] 黄东兰[1] 邱慧芝[1] 王红梅[1] 曹卡加[2] 张伟军[1] 

机构地区：[1]广州医科大学附属肿瘤医院放疗一科,广州510095 [2]中山大学肿瘤防治中心耳鼻咽喉科,广州510060

出　　处：《广西医科大学学报》2016年第4期633-636,共4页Journal of Guangxi Medical University

摘　　要：目的:探讨胸腺五肽对接受单纯放疗或联合放、化疗的鼻咽癌患者远期疗效的影响。方法:选择2005年1月至2005年12月60例符合入选标准的鼻咽癌患者,将其随机分为对照组和用药组,每组各30例。对照组采用单纯放疗或联合放、化疗,用药组在对照组基础上给予胸腺五肽治疗。应用Kaplan-Meier和Log-rank法计算和比较两组患者的5年总生存率、无复发生存率、无转移生存率,应用Cox风险回归模型进行多因素分析。结果:对照组和用药组的5年总生存率分别是46.7%和70.0%,差异具有统计学意义(P<0.05),5年无复发生存率分别为80.0%和86.7%,差异无统计学意义(P>0.05),5年无转移生存率分别是70.0%和83.3%,差异无统计学意义(P>0.05);Cox风险回归模型进行多因素分析,结果显示:分组、N分期、临床分期是影响鼻咽癌总生存的独立预后因素(均P<0.05),临床分期是影响鼻咽癌无复发生存的独立预后因素(P=0.001),分组、性别、N分期、是否化疗是鼻咽癌无转移生存的独立预后因素(均P<0.05)。结论:胸腺五肽可能通过降低鼻咽癌患者转移率从而影响总生存,值得进一步研究。Objective： To investigate the effect of thymopentin on long-term outcomes of patients with nasopharyngealcancer （NPC）. Methods： 60 patients with NPC from January 2005 and December 2005 were enrolledand randomly divided into the control group and the treatm ent group （30 cases in each group）. Thepatients in the treatm ent group received radiotherapy only or radiotherapy combined with chemotherapy,while those in the treatm ent group were treated as the control group with the addition of thymopentin. Kaplan-Meier and log-rank test were used for the evaluation of 5-year overall survival rate （OS） , locoregionalrelapse-free survival （LRFS） and metastasis-free survival （DM FS） , and multivariate Cox regression proportionalwas also used for hazards analysis. Results： The 5-year OS was significantly different between thecontrol group （49. 8% ） and the treatm ent group （49. 8% vs. 70. 0 % 9 P 〈0. 05）. The LRFS and DMFSwere 75. 7 % and 69. 2 % in the control group, and 85. 9% and 83. 1 % in the treatm ent group, but thedifferences were not statistically significant （ P 〉 0 . 05）. M ultivariate analysis revealed that the use of thymopentin,N stage, clinical stages and chemotherapy were independently prognostic factors for the OS ofthe patients with NPC （ P 〈0. 05）. The clinical stage was independently prognostic factor for the LRFS ofthe patients （ P =0. 001）. The use of thym opentin, gender, N stage and chemotherapy were independentlyprognostic factors for the DMFS of the patients （ P = 0 . 001）. Conclusion： Thymopentin can improve thesurvival of patients with NPC through reducing the distant m etastasis of NPC, and further investigation isworthy.

关 键 词：胸腺五肽 鼻咽癌 放疗 联合放、化疗 

分 类 号：R739.6[医药卫生—肿瘤]